Open AccessTHE IMPACT OF VIT-D ON SURVIVAL IN HEMODIALYSIS PATIENTS: A CRITICAL APPRAISAL
Author(s) -
Monali Rajendrakumar Sahu,
Tanvi Wairagade,
Sonali Wairagade,
Ranjit Ambad,
Nandkishor Bankar
Publication year - 2021
Publication title -
journal of medical pharmaceutical and allied sciences
Language(s) - English
Resource type - Journals
ISSN - 2320-7418
DOI - 10.22270/jmpas.v10i4.1198
Subject(s) - medicine , secondary hyperparathyroidism , hemodialysis , parathyroidectomy , dialysis , kidney disease , placebo , vitamin d and neurology , vitamin d deficiency , hyperparathyroidism , randomized controlled trial , gastroenterology , parathyroid hormone , urology , pathology , calcium , alternative medicine
Vit-D deficiency (20 ng / mL) and deficiency (20-29 ng / mL) are common side effects in people with chronic disease V or End stage Renal Disease on dialysis. In addition to the lack of exposure to nutrients and sun, reduced Vit-D and body composition, obesity, and racial differences also play a role. In addition, due to a deficiency of 25 (OH) D, serum levels of 1, 25 (OH) 2D decreased over time in CKD patients, as well as non-invasive detection of 25 (OH) D by associated renal cells, increased fibroblast factor -23, and a decrease in functional tissue. Vit-D deficiency causes secondary hyperparathyroidism and associated side effects, such as high hyperparathyroidism and hypercalcemia, requiring surgical parathyroidectomy or the use of calcimimetics. This document examines the available evidence and underscores the importance of Vit-D supplementation in hemodialysis patients. To assess the strength and critically review the available evidence on impact of Vit-D in survival of hemodialysis patients. Vit-D has a survival advantage in patients with CKD-MBD, however we need randomized controlled trial in hemodialysis patients with matched controls given placebo, to prove benefits of Vit-D in terms of all cause and cause specific mortality.